Forte Biosciences Inc
FBRX21.370USD
-1.280-5.65%
Close 12/12, 16:00（ET）Quotes delayed by 15 min
267.63MMarket Cap
LossP/E TTM
More Details of Forte Biosciences Inc Company
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Forte Biosciences Inc Info
Ticker SymbolFBRX
Company nameForte Biosciences Inc
IPO dateApr 13, 2017
CEOWagner (Paul A)
Number of employees14
Security typeOrdinary Share
Fiscal year-endApr 13
Address3060 Pegasus Park Drive
CityDALLAS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code75247
Phone13106186994
Websitehttps://www.fortebiorx.com/home/default.aspx
Ticker SymbolFBRX
IPO dateApr 13, 2017
CEOWagner (Paul A)
Company Executives of Forte Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Paul A. Wagner, Ph.D.
Dr. Paul A. Wagner, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
82.09K
+1.42%
Mr. Antony A. Riley
Mr. Antony A. Riley
Chief Financial Officer
Chief Financial Officer
31.70K
+0.77%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
5.94K
--
Mr. Steven Kornfeld
Mr. Steven Kornfeld
Independent Director
Independent Director
3.96K
--
Dr. Barbara K. Finck, M.D.
Dr. Barbara K. Finck, M.D.
Director, Senior Medical Clinician
Director, Senior Medical Clinician
--
--
Dr. Stephen K. Doberstein, Ph.D.
Dr. Stephen K. Doberstein, Ph.D.
Independent Director
Independent Director
--
--
Mr. Richard G. (Rich) Vincent, CPA
Mr. Richard G. (Rich) Vincent, CPA
Independent Director
Independent Director
--
--
Dr. Scott C. Brun, M.D.
Dr. Scott C. Brun, M.D.
Independent Director
Independent Director
--
--
Mr. Shiv Kapoor
Mr. Shiv Kapoor
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Paul A. Wagner, Ph.D.
Dr. Paul A. Wagner, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
82.09K
+1.42%
Mr. Antony A. Riley
Mr. Antony A. Riley
Chief Financial Officer
Chief Financial Officer
31.70K
+0.77%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
5.94K
--
Mr. Steven Kornfeld
Mr. Steven Kornfeld
Independent Director
Independent Director
3.96K
--
Dr. Barbara K. Finck, M.D.
Dr. Barbara K. Finck, M.D.
Director, Senior Medical Clinician
Director, Senior Medical Clinician
--
--
Dr. Stephen K. Doberstein, Ph.D.
Dr. Stephen K. Doberstein, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fred Alger Management, LLC
13.06%
Federated Hermes Global Investment Management Corp.
13.05%
Janus Henderson Investors
11.21%
OrbiMed Advisors, LLC
9.56%
Tybourne Capital Management (HK) Limited
6.28%
Other
46.84%
Shareholders
Shareholders
Proportion
Fred Alger Management, LLC
13.06%
Federated Hermes Global Investment Management Corp.
13.05%
Janus Henderson Investors
11.21%
OrbiMed Advisors, LLC
9.56%
Tybourne Capital Management (HK) Limited
6.28%
Other
46.84%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
46.88%
Hedge Fund
20.01%
Private Equity
9.56%
Investment Advisor
7.21%
Corporation
3.92%
Individual Investor
1.02%
Research Firm
0.12%
Other
11.28%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
74
10.85M
55.59%
--
2025Q3
75
10.85M
55.60%
+222.21K
2025Q2
78
10.20M
43.87%
+4.95M
2025Q1
72
5.29M
79.85%
+32.05K
2024Q4
73
5.16M
31.17%
+3.22M
2024Q3
65
789.31K
58.51%
-26.11K
2024Q2
72
815.46K
58.79%
-11.24K
2024Q1
101
826.69K
59.45%
-38.71K
2023Q4
113
819.35K
60.39%
+5.27K
2023Q3
130
814.23K
49.33%
+164.66K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fred Alger Management, LLC
1.62M
13.02%
+708.04K
+77.75%
Jun 30, 2025
Federated Hermes Global Investment Management Corp.
1.48M
11.89%
+406.41K
+37.90%
Aug 31, 2025
Janus Henderson Investors
1.39M
11.22%
+474.85K
+51.61%
Jun 30, 2025
OrbiMed Advisors, LLC
1.20M
9.63%
+603.87K
+101.82%
Jun 30, 2025
Tybourne Capital Management (HK) Limited
786.65K
6.33%
+166.67K
+26.88%
Jun 30, 2025
The Vanguard Group, Inc.
486.92K
3.92%
+397.97K
+447.40%
Jun 30, 2025
Cable Car Capital LLC
500.00K
4.02%
+280.40K
+127.68%
Jun 30, 2025
Sphera Funds Management Ltd.
495.11K
3.98%
+495.11K
--
Jun 30, 2025
Nemean Asset Management, LLC
432.28K
3.48%
+432.28K
--
Nov 22, 2024
Adage Capital Management, L.P.
333.33K
2.68%
+333.33K
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Alger 35 ETF
1.35%
Texas Capital Texas Small Cap Equity Index ETF
0.06%
iShares Micro-Cap ETF
0.01%
Dimensional US Core Equity 1 ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
Alger Mid Cap 40 ETF
0%
Avantis US Small Cap Equity ETF
0%
Alger 35 ETF
Proportion1.35%
Texas Capital Texas Small Cap Equity Index ETF
Proportion0.06%
iShares Micro-Cap ETF
Proportion0.01%
Dimensional US Core Equity 1 ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Fidelity Nasdaq Composite Index ETF
Proportion0%
Alger Mid Cap 40 ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
Date
Type
Ratio
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
FAQs
Who are the top five shareholders of Forte Biosciences Inc?
The top five shareholders of Forte Biosciences Inc are:
Fred Alger Management, LLC holds 1.62M shares, accounting for 13.02% of the total shares.
Federated Hermes Global Investment Management Corp. holds 1.48M shares, accounting for 11.89% of the total shares.
Janus Henderson Investors holds 1.39M shares, accounting for 11.22% of the total shares.
OrbiMed Advisors, LLC holds 1.20M shares, accounting for 9.63% of the total shares.
Tybourne Capital Management (HK) Limited holds 786.65K shares, accounting for 6.33% of the total shares.
Fred Alger Management, LLC holds 1.62M shares, accounting for 13.02% of the total shares.
Federated Hermes Global Investment Management Corp. holds 1.48M shares, accounting for 11.89% of the total shares.
Janus Henderson Investors holds 1.39M shares, accounting for 11.22% of the total shares.
OrbiMed Advisors, LLC holds 1.20M shares, accounting for 9.63% of the total shares.
Tybourne Capital Management (HK) Limited holds 786.65K shares, accounting for 6.33% of the total shares.
What are the top three shareholder types of Forte Biosciences Inc?
The top three shareholder types of Forte Biosciences Inc are:
Fred Alger Management, LLC
Federated Hermes Global Investment Management Corp.
Janus Henderson Investors
Fred Alger Management, LLC
Federated Hermes Global Investment Management Corp.
Janus Henderson Investors
How many institutions hold shares of Forte Biosciences Inc (FBRX)?
As of 2025Q4, 74 institutions hold shares of Forte Biosciences Inc, with a combined market value of approximately 10.85M, accounting for 55.59% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.00%.
What is the biggest source of revenue for Forte Biosciences Inc?
In --, the -- business generated the highest revenue for Forte Biosciences Inc, amounting to -- and accounting for --% of total revenue.
